SA
NBIX icon

Sanctuary Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Sanctuary Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04M Sell
7,879
-571
-7% -$75.8K 0.01% 1312
2025
Q4 		$1.2M Buy
8,450
+388
+5% +$56.2K 0.01% 1226
2025
Q3 		$1.13M Buy
8,062
+1,450
+22% +$196K 0.01% 1219
2025
Q2 		$831K Buy
6,612
+2,656
+67% +$305K 0.01% 1331
2025
Q1 		$437K Sell
3,956
-4,235
-52% -$536K ﹤0.01% 1599
2024
Q4 		$1.26M Buy
8,191
+542
+7% +$67K 0.01% 1117
2024
Q3 		$961K Buy
7,649
+3,898
+104% +$534K 0.01% 1268
2024
Q2 		$510K Buy
+3,751
New +$514K ﹤0.01% 1626

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanctuary Advisors's NBIX Position: Q1 2026 in Review

Sanctuary Advisors reduced its Neurocrine Biosciences (NBIX) stake by 6.8% in Q1 2026, selling an estimated $75.8K and leaving 7,879 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #1312.

Sanctuary Advisors first reported a position in NBIX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.26M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Sanctuary Advisors held 7,879 shares of Neurocrine Biosciences worth $1.04M as of Q1 2026.
  • Sanctuary Advisors sold 571 Neurocrine Biosciences shares in Q1 2026, an estimated $75.8K.
  • Neurocrine Biosciences made up 0.01% of Sanctuary Advisors's portfolio in Q1 2026, its #1312 holding.
  • Sanctuary Advisors first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 8 quarters since.
  • Sanctuary Advisors's Neurocrine Biosciences position peaked at $1.26M in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Sanctuary Advisors's 13F filing for Q1 2026, filed 5 May 2026.